Latest Regulation News

Page 14 of 166
Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.
Victor Sage
Victor Sage
16 Oct 2026
Latrobe Magnesium says its Phase 1B demonstration plant is 95% installed and 35% commissioned, keeping first magnesium metal crowns above 98% purity on track for the end of 2026. The operational advance comes alongside a tight funding position, an extended A$3.4 million entitlement offer and an ambitious South Carolina expansion plan.
Victor Sage
Victor Sage
16 Oct 2026
Resimac Group delivered a stronger FY26, with normalised NPAT up 26% to $49.9 million and total assets under management reaching a record $16.5 billion. The result supports higher ordinary dividends, but the lender is still managing asset finance run-off, ASIC hardship proceedings and longer-term funding risks.
Claire Turing
Claire Turing
16 Oct 2026
Fiducian Group delivered double-digit growth in underlying profit and lifted its fully franked dividend, despite a one-off $7.95 million ASIC penalty dragging statutory earnings lower. The wealth manager is also betting on AI-enabled adviser productivity and expansion of its external platform business.
Claire Turing
Claire Turing
15 Oct 2026
Chorus has retained its BBB issuer credit rating with a positive outlook after S&P reclassified NZ$683 million of government-linked securities as debt. The change lifts adjusted leverage, but S&P still sees a possible upgrade to BBB+ if Chorus keeps FFO-to-debt above 13% and maintains supportive financial policies.
Sophie Babbage
Sophie Babbage
15 Oct 2026
GenusPlus has won approximately $255 million of power infrastructure work from Western Power and Fortescue, extending its project pipeline into 2029. The awards span renewable energy connections, network maintenance and mine-site decarbonisation infrastructure, although individual contract values and margins remain undisclosed.
Nora Hopper
Nora Hopper
14 Oct 2026
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
Victor Sage
14 Oct 2026
Euroz Hartleys says several conditions for its A$145 million sale of the Capital Markets business to BMO have now been satisfied, leaving shareholder approval and Canadian Bank Act approval among the key remaining gates. Completion remains on track for the December quarter.
Claire Turing
Claire Turing
14 Oct 2026
ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.
Victor Sage
Victor Sage
14 Oct 2026
IAG has offered a package of competition remedies to support approval of its proposed 20-year insurance alliance with RAC of Western Australia, including the transfer of NRMA policy renewal rights and a $20 million community investment. The insurer says the transaction still carries $1.2 billion in additional annual gross written premium and approximately $100 million in annual pre-tax synergies once integration is complete.
Victor Sage
Victor Sage
14 Oct 2026
Forrestania Resources has extended its takeover offer for Zenith Minerals to 12 November after Takeovers Panel findings forced corrective disclosure and new shareholder protections. The bidder says it has 49.43% acceptances and a 58.54% relevant interest, but restrictions will limit its voting and control rights even if the offer succeeds.
Maxwell Dee
Maxwell Dee
13 Oct 2026
Image Resources says it knows of no undisclosed information that could explain its share price more than doubling between 9 and 13 October. The response follows an ASX price query prompted by the move and a surge in trading volume.
Maxwell Dee
Maxwell Dee
13 Oct 2026

Browse the archive

Full archive